Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging human papillomavirus vaccines.

Neil D Christensen1

  • 1The Pennsylvania State University College of Medicine, The Department of Microbiology and Immunology, Hershey, PA 17033, USA. ndc1@psu.edu

Expert Opinion on Emerging Drugs
|March 11, 2005
PubMed
Summary

Human papillomavirus (HPV) vaccines show promise for preventing and treating HPV-related cancers. Preventive vaccines are successful, while therapeutic vaccines are advancing with combination strategies for better efficacy against HPV infections.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The full transcription map of cottontail rabbit papillomavirus in tumor tissues.

PLoS pathogens·2024
Same author

Monitoring mouse papillomavirus-associated cancer development using longitudinal Pap smear screening.

mBio·2024
Same author

Immune Responses in Oral Papillomavirus Clearance in the MmuPV1 Mouse Model.

Pathogens (Basel, Switzerland)·2023
Same author

Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies.

Journal of pharmaceutical sciences·2022
Same author

Modeling HPV-Associated Disease and Cancer Using the Cottontail Rabbit Papillomavirus.

Viruses·2022
Same author

Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.

Journal of pharmaceutical sciences·2022

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • Human papillomavirus (HPV) is a major cause of anogenital, oropharyngeal, and cutaneous cancers, with cervical cancer being the most prevalent, causing ~500,000 deaths annually.
  • High-risk HPV types are responsible for most HPV-associated cancers, necessitating effective prevention and treatment strategies.

Purpose of the Study:

  • To review the current landscape of human papillomavirus (HPV) vaccines, focusing on preventive and therapeutic approaches.
  • To highlight advancements in HPV vaccine research, including strategies to overcome type-specificity and enhance therapeutic efficacy.

Main Methods:

  • Review of preclinical animal models and human clinical trials for HPV vaccines.
  • Analysis of various therapeutic vaccine strategies, including genetic, recombinant virus, dendritic cell-based, and combination approaches targeting viral oncogenes E6 and E7.

Main Results:

  • Preventive HPV virus-like particle (VLP) vaccines have demonstrated clear success in clinical trials.
  • Current therapeutic HPV vaccine trials show limited disease clearance, but combination strategies exhibit enhanced efficacy in preclinical models.

Conclusions:

  • HPV VLP vaccines are effective for prevention.
  • Combination therapeutic strategies show promise for enhancing cell-mediated immunity and await further clinical testing for HPV infection clearance.
  • HPV vaccines represent a significant advancement in the prevention and potential cure of HPV infections.

Related Experiment Videos